Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
4(66.7%)
N/A
1(16.7%)
Phase 2
1(16.7%)
6Total
Early Phase 1(4)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04674722Early Phase 1Completed

HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody

Role: collaborator

NCT02978196Early Phase 1Completed

99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC

Role: collaborator

NCT04158817Early Phase 1Completed

68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage

Role: collaborator

NCT04040686Early Phase 1Completed

HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02

Role: collaborator

NCT04992715Phase 2Unknown

PD-L1 Expression in Lung Cancer

Role: lead

NCT04436406Not ApplicableUnknown

PD-L1 Expression in Cancer (PECan Study).

Role: collaborator

All 6 trials loaded